Keshava Kumar
Bristol-Myers Squibb
9 Papers
18 Citations
Keshava Kumar is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Myeloid leukemia & Maintenance therapy. The author has an hindex of 3, co-authored 9 publications.
Chat about Author
Papers
CC-486 Reduces Hospitalization and Associated Estimated Costs in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy: Results from the QUAZAR AML-001 Maintenance Trial
Esther Oliva,Suman Kambhampati,Suman Kambhampati,Albert Oriol,Ignazia La Torre,Barry S. Skikne,Barry S. Skikne,C.L. Beach,Keshava Kumar,Qian Dong,Clara Chen,Sandip Ranjan,Zephirin Kiendrebeogo,Thorsten Braun +13 more
TL;DR: The QUAZAR AML-001 Maintenance Trial as mentioned in this paper showed that CC-486, an oral hypomethylating agent, significantly prolonged overall (OS) and relapse-free survival (RFS) vs. placebo (PBO) in pts with newly diagnosed (ND) AML in first remission following IC.
8
Health-related quality of life (HRQoL) in the phase III QUAZAR-AML-001 trial of CC-486 as maintenance therapy for patients with acute myeloid leukemia (AML) in first remission following induction chemotherapy (IC).
Gail J. Roboz,Hartmut Döhner,Christopher Pocock,Hervé Dombret,Farhad Ravandi,Jun Ho Jang,Dominik Selleslag,Jiri Mayer,Uwe M. Martens,Jane L. Liesveld,Teresa Bernal del Castillo,Ming-Chung Wang,Ignazia La Torre,Barry Skikne,Keshava Kumar,Qian Dong,Julia Braverman,Salem Abi Nehme,C.L. Beach,Andrew H. Wei +19 more
TL;DR: Results from the phase III QUAZAR AML-0070 trial confirmed that once-weekly dexamethasone treatment with a prophylactic tablet reduces the risk of relapse and prolong survival without compromising HRQoL.
5
CC-486 Mechanism Imparted By Extended Exposure of Azacitidine Upregulates Myeloid Differentiation Markers and Induces Cell Death in AML Cells
Diana Ronai Dunshee,Dai Yumin,Jessica C. Jang,Alberto Risueño,Danny V Jeyaraju,Patrick Hagner,Wendy L. See,Kyle J. MacBeth,Xiaomin Wang,Ignazia La Torre,Barry S. Skikne,Barry S. Skikne,C.L. Beach,Keshava Kumar,Anjan Thakurta,Daniel Menezes +15 more
TL;DR: The kinetics of expression of myeloid markers of cellular differentiation and cytotoxicity with various AZA dosing schedules in in vitro and in vivo models of AML were assessed, suggesting that cell division is a requirement for AZA-induced CD11b changes.
3
Escalated dosing schedules of CC-486 for patients experiencing first acute myeloid leukemia (AML) relapse: Results from the phase III QUAZAR AML-001 maintenance trial.
Hartmut Döhner,Andrew H. Wei,Pau Montesinos,Hervé Dombret,Farhad Ravandi,Hamid Sayar,Kimmo Porkka,Irwindeep Sandhu,Francesco Passamonti,Fabrizio Pane,Tadeusz Robak,Jose F Falantes,Andre C. Schuh,Gert J. Ossenkoppele,Ignazia La Torre,Barry Skikne,Keshava Kumar,Qian Dong,C.L. Beach,Gail J. Roboz +19 more
TL;DR: CC-486 is an oral hypomethylating agent that reduces the risk of relapse in patients with recurrent AML by suppressing growth of residual leukemic cells post-induction.
3
Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial
Farhad Ravandi,Christopher Pocock,Dominik Selleslag,Pau Montesinos,Hamid Sayar,Maurizio Musso,Angela Figuera Alvarez,Hana Safah,William Tse,Sang Kyun Sohn,Devendra K Hiwase,Timothy Chevassut,Francesca Pierdomenico,Ignazia La Torre,Barry S. Skikne,Barry S. Skikne,Keshava Kumar,Qian Dong,C.L. Beach,Hervé Dombret +19 more
TL;DR: Most GI-related TEAEs reported by patients treated with CC-486 were low-grade, and events decreased in frequency after initial treatment cycles, indicating these events were well managed.
2